Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: RTX stock price vs GILD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at GILD's multiple
Needs GILD P/E.
Implied fair value · at RTX's multiple
Needs RTX P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
RTX CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
GILEAD SCIENCES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
General Electric Company
RTX vs GE
HONEYWELL INTERNATIONAL INC
RTX vs HON
Parker-Hannifin Corp
RTX vs PH
Spirit AeroSystems Holdings, Inc.
RTX vs SPR
TransDigm Group INC
RTX vs TDG
AbbVie Inc.
RTX vs ABBV
AMGEN INC
RTX vs AMGN
BRISTOL MYERS SQUIBB CO
RTX vs BMY
Merck & Co., Inc.
RTX vs MRK
PFIZER INC
RTX vs PFE
REGENERON PHARMACEUTICALS, INC.
RTX vs REGN
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe RTX can sustain its 9.7% revenue growth while expanding margins toward GILD levels, then hold or consider adding; otherwise, reduce exposure because RTX trades at a 43.4x P/E and the provided valuation work implies 55.7% downside.
RTX trades at a meaningful premium to GILD on earnings, with a 43.4x P/E versus 19.2x for GILD, yet the valuation output implies a price of $95.26, or 55.7% downside from the current $215.22. The fact that RTX is still above both its historical band and the DCF range suggests the market is already pricing in a lot of optimism.
Supporting Metrics
